USCRF Board of Directors Meeting
February 2004
Cancer Therapeutics (MUSC, USC)
•As
both a practical and financial endeavor, the discovery and development of new anticancer drugs is a
high priority goal.
•Currently,
annual sales of drugs run into the billions of dollars and considerable resources are devoted to
improving therapeutic interventions in cancer.
• NIH has a funding priority for investigator
initiated research programs that target development and
characterization of new drugs. In order to leverage such grants, academic
investigators benefit
significantly from direct associations with the pharmaceutical sector.